The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients.
- Author:
Soyi LIM
1
;
Yun Hwan KIM
;
Kwang Beom LEE
;
Jong Min LEE
Author Information
- Publication Type:Original Article
- Keywords: Endometrial Neoplasms; Hormone Replacement Therapy; Drospirenone; Estradiol
- MeSH: Body Mass Index; Case-Control Studies; Disease-Free Survival; Endometrial Neoplasms*; Estradiol; Female; Gynecology; Hormone Replacement Therapy; Humans; Logistic Models; Mortality; Multivariate Analysis; Obstetrics; Parity; Propensity Score; Recurrence; Retrospective Studies; Survivors
- From:Journal of Gynecologic Oncology 2018;29(5):e72-
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: To determine whether drospirenone/estradiol (DRSP/E2) has an adverse effect on clinical outcomes in surgically staged International Federation of Gynecology and Obstetrics (FIGO) stage I/II endometrial cancer (EC) patients. METHODS: In a retrospective case-controlled study, 58 women with EC who had received DRSP/E2 postoperatively were compared with 116 women who had not. And, oncologic safety of postoperative hormone therapy with DRSP/E2 in EC survivors were compared between the 2 groups after propensity score matching using a logistic regression model. RESULTS: The median ages were 47.7 years and 53.6 years for the study and the control groups, respectively (p < 0.001). The study group had similar parity (p = 0.71), lower body mass index (p = 0.03) and more premenopausal women (p < 0.001) than the control group. The stages were completely matched. The grades (p = 0.42), lymphovascular space invasion (p = 0.23), preoperative cancer antigen 125 (CA 125) level (p = 0.89), and hormone receptor status (p = 0.07) were similar in both groups. The median tumor diameter was statistically larger in the study group than in the control group (p < 0.001). Both group received similar adjuvant therapy (p = 0.80). In the propensity matching, only hormone receptor status was significantly different (p = 0.03). In the univariate analysis, only stage was significantly associated with disease-free survival (DFS) and there was no variable associated with overall survival (OS). And, there was no significant factor identified in multivariate analysis. The difference in the DFS (p = 0.63) and in the OS (p = 0.32) was not significant. The same results were obtained after propensity score matching. CONCLUSION: Postoperative hormone therapy with DRSP/E2 in EC survivors did not increase recurrence or the death rate.
